Biopharmas raising money in public or private financings, including: Adma, Atara, Cel-Sci, Curis, Edgewise, Forma, Frazier Lifesciences, Hookipa, IGM, Kura, Pepgen, Qu, Reneo, Rocket, Sigilon, Silverback, Sutro, Syndax, Syros, Xphyto.

Rayzebio Inc. has swiftly followed up its recent $45 million series A round with a $105 million series B round that attracted several top-tier crossover investors.

Biopharmas raising money in public or private financings, including: Achieve, Alx, Amryt, Arcturus, Ibio, IGM, Kinnate, Kura, Marinus, Nuance, Progenity, Regulus, Repligen, Scineuro, Sutro, Syndax, Vigil.

Biopharmas raising money in public or private financings, including: 4D Molecular, Abcellera, Basking, Biocryst, Cogent, Enliven, Helix, Intellia, Nanobiotix, Repligen, Sinovac, Spirea, Trianni.

Biopharmas raising money in public or private financings, including: Burning Rock, Nicox, Reata, Sigilon, Silverback.

Biopharmas raising money in public or private financings, including: Bioage, Codexis, I2o, Kinnate, Neuroglee, Ortho Regenerative, Rubedo, Silverback.

Chinese biopharma Impact Therapeutics Inc. of Nanjing raised $50 million in a series C+ round on Nov. 30, two years after its $30 million series C round. Impact’s CEO Jun Bao told BioWorld that the majority of the proceeds would be used to take several programs forward. The financing round also paved the way toward an IPO.